Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens
Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are aggressive tumors of mature B cells that are distinguished by a combination of histomorphological, phenotypic, and genetic features. A subset of B-cell lymphomas, however, has one or more characteristics that overlap BL and DLBCL, and are categorized as B-cell lymphoma unclassifiable, with features intermediate between BL and DLBCL (BCL-U). Molecular analyses support the concept that there is a biological continuum between BL and DLBCL that includes variable activity of MYC, an oncoprotein once thought to be only associated with BL, but now recognized as a major predictor of survival among patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Christopher D. Carey, Daniel Gusenleitner, Bjoern Chapuy, Alexandra E. Kovach, Michael J. Kluk, Heather H. Sun, Rachel E. Crossland, Chris M. Bacon, Vikki Rand, Paola D. Cin, Long P. Le, Donna Neuberg, Aliyah R. Sohani, Margaret A. Shipp, Stefano Monti, S Tags: Regular Article Source Type: research
More News: Burkitt Lymphoma | Genetics | Lymphoma | Molecular Biology | Pathology | Prednisone | Rituxan